10 false false false false false false false false false false true false false false false false false No description of principal activity 2024-06-01 Sage Accounts Production Advanced 2024 - FRS102_2024 1,956 1,304 652 1,956 652 xbrli:pure xbrli:shares iso4217:GBP 09052134 2024-06-01 2025-05-31 09052134 2025-05-31 09052134 2024-05-31 09052134 2023-06-01 2024-05-31 09052134 2024-05-31 09052134 2023-05-31 09052134 bus:Director8 2024-06-01 2025-05-31 09052134 core:WithinOneYear 2025-05-31 09052134 core:WithinOneYear 2024-05-31 09052134 core:ShareCapital 2025-05-31 09052134 core:ShareCapital 2024-05-31 09052134 core:RetainedEarningsAccumulatedLosses 2025-05-31 09052134 core:RetainedEarningsAccumulatedLosses 2024-05-31 09052134 bus:Director1 2024-06-01 2025-05-31 09052134 bus:SmallEntities 2024-06-01 2025-05-31 09052134 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 09052134 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 09052134 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 09052134 bus:FullAccounts 2024-06-01 2025-05-31 09052134 core:ComputerEquipment 2024-06-01 2025-05-31 09052134 core:OfficeEquipment 2025-05-31 09052134 core:OfficeEquipment 2024-05-31 09052134 core:OfficeEquipment 2024-06-01 2025-05-31 09052134 core:KeyManagementPersonnel 2024-06-01 2025-05-31
COMPANY REGISTRATION NUMBER: 09052134
Ashford Clinical Providers Ltd
Filleted Unaudited Financial Statements
31 May 2025
Ashford Clinical Providers Ltd
Financial Statements
Year ended 31 May 2025
Contents
Page
Statement of financial position
1
Notes to the financial statements
3
Ashford Clinical Providers Ltd
Statement of Financial Position
31 May 2025
2025
2024
Note
£
£
Fixed assets
Tangible assets
5
652
Current assets
Debtors
6
316,475
91,909
Cash at bank and in hand
1,146,275
1,139,698
------------
------------
1,462,750
1,231,607
Creditors: amounts falling due within one year
7
875,647
657,201
------------
------------
Net current assets
587,103
574,406
---------
---------
Total assets less current liabilities
587,103
575,058
---------
---------
Net assets
587,103
575,058
---------
---------
Capital and reserves
Called up share capital
137
137
Profit and loss account
586,966
574,921
---------
---------
Shareholders funds
587,103
575,058
---------
---------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
Ashford Clinical Providers Ltd
Statement of Financial Position (continued)
31 May 2025
These financial statements were approved by the board of directors and authorised for issue on 15 July 2025 , and are signed on behalf of the board by:
Dr S Rashid
Director
Company registration number: 09052134
Ashford Clinical Providers Ltd
Notes to the Financial Statements
Year ended 31 May 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Camburgh House, 27 New Dover Road, Canterbury, Kent, CT1 3DN, United Kingdom.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Computer equipment
-
33% straight line
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 10 (2024: 10 ).
5. Tangible assets
Equipment
£
Cost
At 1 June 2024 and 31 May 2025
1,956
-------
Depreciation
At 1 June 2024
1,304
Charge for the year
652
-------
At 31 May 2025
1,956
-------
Carrying amount
At 31 May 2025
-------
At 31 May 2024
652
-------
6. Debtors
2025
2024
£
£
Other debtors
316,475
91,909
---------
--------
7. Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
186,724
230,411
Corporation tax
52,300
57,200
Other creditors
636,623
369,590
---------
---------
875,647
657,201
---------
---------
8. Related party transactions
During the year dividends of £146,224 (2024: £115,852) were paid to the Directors of the company.